[
    "{\"step_by_step_thinking\": \"Document [0] states that ofatumumab is approved in several countries for the treatment of relapsing forms of multiple sclerosis (MS). It was found to be more effective than oral teriflunomide in reducing the annualized relapse rate, as well as reducing MRI-detected lesion activity and limiting worsening of disability. Document [1] also supports the efficacy of ofatumumab in reducing relapse and disability progression risk. Document [18] also mentions that ofatumumab was associated with lower annualized relapse rates than teriflunomide. These documents provide strong evidence that ofatumumab is effective for multiple sclerosis.\", \"answer_choice\": \"A\"}"
]